MGMT and malignant glioma: Similarly, MGMT promoter methylation was associated with improved survival in our cohort.[17] This finding is well supported by clinical trials and translational studies showing that MGMT methylation status predicts better response to temozolomide chemotherapy and is correlated with longer survival in malignant gliomas.